Emgrast 300 mcg Injection is an analogue of the human granulocyte colony-stimulating factor (G-CSF). It stimulates white blood cell growth and helps reduce the risk of infection in patients undergoing chemotherapy for cancer. Patients with blood disorders are advised not to take this medicine.
Emgrast 300 Injection may cause some common adverse effects such as weakness, bone pain, rashes, bone pain, and pain or redness at the site of injection is common. However, inform your doctor if you notice a lump, swelling or bruise that does not go away. It may not protect you from all types of infections, so inform your doctor if you notice fever, chills, rash, sore throat, or swelling of the face or neck.
Emgrast Injection is not prescribed for breastfeeding and pregnant women. You must use an effective contraceptive during the therapy to avoid pregnancy. Drink adequate fluids to prevent dehydration.
Patients with Cancer Receiving Myelosuppressive Chemotherapy: Emgrast 300 Injection is used to reduce the incidence of infections manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever.
Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy: Emgrast 300 is indicated to shorten the time to neutrophil recovery and duration of fever after induction or consolidation chemotherapy in patients with acute myeloid leukaemia (AML).
Patients with Cancer Undergoing Bone Marrow Transplantation: Emgrast 300 mcg Injection is indicated to shorten the duration of neutropenia and the clinical sequelae associated with neutropenia, ex. febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.
Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy: Emgrast 300 mcg Injection is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.
Patients with Severe Chronic Neutropenia: Emgrast 300 mcg Injection is indicated for chronic administration to reduce the frequency and duration of sequelae of severe neutropenia (e.g., fever, infection, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia.
Emgrast is used to stimulate the production of white blood cells, which play a critical role in the body's immune system. White blood cells help protect the body against infection and disease by attacking and eliminating harmful bacteria and viruses. By increasing the number of white blood cells in the body.
Emgrast Injection may help reduce the risk of infection in people with neutropenia, a condition characterized by a low number of neutrophils, a type of white blood cell.
Emgrast 300 mcg helps reduce the duration of neutropenia and the need for neutropenia-related hospitalizations in people undergoing chemotherapy for cancer. It may also be used to reduce the incidence of febrile neutropenia, a potentially serious complication of chemotherapy that involves fever and low white blood cell counts.
Overall, the main benefit of Emgrast is its ability to help boost the body's immune system and protect against infection.
Emgrast Injection stimulates the production of neutrophil granulocytes, a type of white blood cell that protects the body from infection. This happens by activating cells in the bone marrow called stem cells, which are responsible for producing neutrophils and other types of blood cells. When neutrophil levels are low, the body becomes more susceptible to infection. By increasing the production of neutrophils. Emgrast 300 mcg Injection helps reduce the risk of infection in people with neutropenia.
It is generally not recommended to drink alcohol while taking Emgrast 300 Injection. It may increase the risk of liver damage. it is best to avoid alcohol or limit your alcohol consumption while taking any medication.
It is not known whether Emgrast 300 passes into breast milk. If you are breastfeeding and taking Emgrast 300 mcg Injection it is important to talk to your doctor about the potential risks and benefits of continuing to breastfeed. Your doctor will be able to help you make the best decision for you and your baby's health.
Emgrast Injection is safe to use in patients with liver disease. No dose adjustment of Emgrast 300 Injection is recommended. If you experience any side effects please consult your doctor.
Emgrast Injection is safe to use in patients with kidney disease. No dose adjustment of Emgrast 300 Injection is recommended. If you experience any side effects please consult your doctor.
Emgrast 300 mcg Injection is unlikely to affect your ability to drive or operate machinery. If you experience any side effects while taking Emgrast 300 mcg Injection such as dizziness or drowsiness, it is important to avoid driving or operating heavy machinery until the side effects have resolved.
Use of Emgrast 300 Injection may be unsafe during pregnancy as animal studies indicate that it may harm the developing foetus. However, if you are pregnant or planning to become pregnant, it is important to talk to your doctor about the potential risks and benefits of taking Emgrast Injection during pregnancy. Your doctor will be able to help you make the best decision for you and your baby's health.